You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泛生子(GTH.US)公布Q1业绩:核心业务收入同增52.9%,整体毛利率提升至59.3%
格隆汇 05-24 20:16

2021年5月24日,专注于提供肿瘤分子检测、癌症早筛和伴随诊断开发服务的中国癌症精准医疗公司泛生子(GTH.US)公布了其截至2021年第一季度未经审计的财务报告。

财务亮点

2021年第一季度,公司实现总营收92.1百万元人民币,同比增长19.8%。剔除2020年第一季度新型冠状病毒核酸检测Genetron SARS-CoV-2 RNA Test(简称“新冠试剂盒”)的销售收入16.6百万元人民币,核心业务收入同比增长52.9%。2021年第一季度毛利率从2020年同期的55.0%提升至59.3%。

2021年第一季度,公司实现诊断和监测业务收入87.1百万元人民币,同比增长30.4%。其中,前沿的液体活检肝癌早筛检测(简称“HCCscreen”)和诊断业务LDT检测服务,共同推动LDT服务收入强劲增长51.0%,达71.8百万元人民币;IVD产品收入为15.3百万元人民币。剔除新冠试剂盒的销售额,IVD的基本销售额同比增长近5倍。

运营亮点

泛生子宣布了两项重磅的战略合作,分别与京东健康(06618.HK)和西门子医疗达成合作,即通过京东健康的在线医疗健康平台推广泛生子的HCCscreen和人类8基因突变联合检测试剂盒(半导体测序法)(国械注准20203400072,简称“肺癌8基因试剂盒”),以及与西门子医疗战略合作,推进基因测序仪GENETRON S5(国械注准20193220820)和肺癌8基因试剂盒在中国医院市场大规模应用。

2021年1月,泛生子与中生制药(01177.HK)旗下子公司正大天晴就HCCscreen达成中国医院市场独家战略合作关系。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account